GlaxoSmithKline Consumer Healthcare Limited has declared its financial results for the first quarter ended June 30, 2018. The comparable* Revenue for the company recorded a growth of 16.4%. The quarter reported revenue of Rs. 1107 crore, while the PBT was at Rs. 312 crores, a growth of 52%. The quarter also witnessed an increase in volume growth at 12.8%.
Commenting on the results, Navneet Saluja, Managing Director, GlaxoSmithKline Consumer Healthcare Limited said, “We witnessed a positive growth in the first quarter on the back of strong performance of Horlicks and Boost. Our consumer campaigns have been well accepted and they have provided suitable growth momentum. All the channels including rural have performed well and our direct rural foothold now reaches over 22,000 villages.
Investments behind fast-growing segments of high science, such as Protein +, Growth +, and new formats like Boost Ready-to-drink, are showing good uptakes. Our access agenda continues to gain in strength and today our various SKU’s reach out to over 1.78 MN outlets.
With strong business fundamentals, high science-based products, and committed team, we are well poised to deliver a healthy year.” added Saluja.
Performance Highlights:
- Health food drink portfolio continues to be the market leader with 54% value share**
- A strong performance by Horlicks and Boost that witnessed 18% growth
- Boost continues to maintain its strong growth momentum with double-digit volume growth.
- Boost forayed into an all-new Ready to Drink (RTD) format in Tamil Nadu.